Acurx Pharmaceuticals (ACXP) Competitors $0.50 -0.01 (-1.92%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. AADI, CNTX, ANVS, RNXT, AVTX, IPSC, KLTO, VTVT, BLUE, and PRLDShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Aadi Bioscience (AADI), Context Therapeutics (CNTX), Annovis Bio (ANVS), RenovoRx (RNXT), Avalo Therapeutics (AVTX), Century Therapeutics (IPSC), Klotho Neurosciences (KLTO), vTv Therapeutics (VTVT), bluebird bio (BLUE), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Aadi Bioscience Context Therapeutics Annovis Bio RenovoRx Avalo Therapeutics Century Therapeutics Klotho Neurosciences vTv Therapeutics bluebird bio Prelude Therapeutics Acurx Pharmaceuticals (NASDAQ:ACXP) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Do analysts rate ACXP or AADI? Acurx Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 1,496.81%. Aadi Bioscience has a consensus price target of $1.67, indicating a potential downside of 13.64%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Acurx Pharmaceuticals is more favorable than Aadi Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aadi Bioscience 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor ACXP or AADI? In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for Acurx Pharmaceuticals and 0 mentions for Aadi Bioscience. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Aadi Bioscience's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Very Positive Aadi Bioscience Neutral Do insiders and institutionals believe in ACXP or AADI? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 26.0% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ACXP or AADI more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -526.78% -223.78% Aadi Bioscience -246.06%-71.87%-57.28% Which has preferable earnings and valuation, ACXP or AADI? Acurx Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$0.70-0.72Aadi Bioscience$25.07M1.90-$65.76M-$2.35-0.82 Which has more risk and volatility, ACXP or AADI? Acurx Pharmaceuticals has a beta of -1.38, meaning that its stock price is 238% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. SummaryAcurx Pharmaceuticals beats Aadi Bioscience on 9 of the 15 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.76M$2.88B$5.52B$8.87BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-0.7221.6626.5019.82Price / SalesN/A267.10410.19110.66Price / CashN/A41.2925.8827.49Price / Book16.707.277.945.39Net Income-$14.10M-$55.05M$3.15B$248.34M7 Day Performance-20.48%-0.47%1.08%1.25%1 Month Performance31.05%6.59%5.34%5.41%1 Year Performance-76.59%0.42%32.80%18.07% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.801 of 5 stars$0.50-1.9%$8.00+1,496.8%-77.3%$11.76MN/A-0.723Positive NewsAADIAadi Bioscience0.6127 of 5 stars$2.09+2.0%$1.67-20.3%+32.2%$51.62M$25.07M-0.9240High Trading VolumeCNTXContext Therapeutics3.4564 of 5 stars$0.56-1.6%$6.00+965.0%-67.3%$51.37MN/A-1.827ANVSAnnovis Bio1.6198 of 5 stars$2.64+1.5%$30.25+1,045.8%-62.2%$50.66MN/A-1.223RNXTRenovoRx3.0383 of 5 stars$1.41+2.2%$7.25+414.2%+16.4%$50.47M$40K-3.536Gap DownHigh Trading VolumeAVTXAvalo Therapeutics3.3351 of 5 stars$4.79+3.2%$30.00+526.3%-60.0%$50.24M$440K0.0040Positive NewsIPSCCentury Therapeutics2.7938 of 5 stars$0.58-1.2%$4.20+630.4%-78.1%$50.14M$6.59M-1.98170KLTOKlotho NeurosciencesN/A$1.20-22.1%N/AN/A$50.04MN/A-3.33N/ANews CoverageGap DownVTVTvTv Therapeutics2.0489 of 5 stars$15.61+0.4%$35.50+127.5%-15.1%$49.66M$1.02M-5.189Gap DownBLUEbluebird bio2.1344 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520PRLDPrelude Therapeutics3.3722 of 5 stars$0.84-2.4%$4.50+435.7%-78.8%$48.58M$7M-0.50120Gap Down Related Companies and Tools Related Companies Aadi Bioscience Alternatives Context Therapeutics Alternatives Annovis Bio Alternatives RenovoRx Alternatives Avalo Therapeutics Alternatives Century Therapeutics Alternatives Klotho Neurosciences Alternatives vTv Therapeutics Alternatives bluebird bio Alternatives Prelude Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredFine. Don’t believe me. They called me an alarmist... When in 2010 I said America’s debt was out of control. When I warned it w...Porter & Company | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
